gemcitabine, a standard drug for PC therapy, is minimally effective, improving patient's survival by only months. 3 Surgery, currently the only realistic option, is rarely curative, with only about 20% of PC cases being amendable to potentially curative resection, 2 either due to metastasis or involvement of major blood vessels. Therefore, it is critical to develop new agents for the effective management of PC.
Mutations of the Ras family of genes occur in approximately 95% of
PCs. 4 Oncogenic Kras is essential for both the initiation and maintenance of PC. 5 During all stages of pancreatic carcinogenesis, Kras upregulates inflammatory, and signaling pathways that mediate paracrine interactions between epithelial and their surrounding microenvironment.
These Kras-dependent pathways drive tumorigenesis. 6 Given the predominant role of Ras oncogene in pancreatic carcinogenesis, there is an intense ongoing effort to identify inhibitors of the Ras protein. 5, 7 A suitable strategy in designing novel agents is the chemical modification of known drugs in order to optimize their pharmacological properties, primarily their efficacy. Curcumin (diferuloyl-methane) has been extensively studied and has shown some anticancer efficacy in various types of cancer, 8 including PC. 9, 10 However, due to its poor bioavailability, curcumin has only been shown to be effective in in vitro studies and is not currently utilized as an adjuvant to common chemotherapeutics for treating PC. 11 Given this problem, significant efforts have been made to modify curcumin synthetically and producing other curcumin analogs, in order to generate compounds with greater bioavailability and efficacy in vivo. [12] [13] [14] Among these efforts, our group has developed various structural analogues of curcumin (polyenolic zinc-binding agents; PEZBINs), including the current lead compound, CMC2.24 [15] [16] [17] [18] [19] [20] ( Figure 1A ), which has higher bioactivity, better solubility, and no evidence of toxicity even at very high doses. 19, 20 In the present study, we examined, for the first time, the efficacy, and mechanism of action of CMC2.24 in preclinical models of PC. Our data show that CMC2.24 inhibits the growth of human PC in nude mice and in patient-derived tumor xenografts. Furthermore, CMC2.24 strongly suppresses Ras activation leading to a robust inhibition of the RAF-MEK-ERK pathway, followed by reduction in p-STAT3 Ser727 levels, an increase in mitochondrial reactive oxygen species and induction of intrinsic apoptosis.
| MATERIALS AND METHODS
Reagents. Chemically-modified curcumin (CMC2.24; TRB-N0224) was a gift from Traverse Biosciences Inc. (Stony Brook, NY). Curcumin (>98% purity) was purchased from Thermo Fisher Scientific (Waltham, MA). We prepared a 100 mM stock solution of CMC2.24 and curcumin in DMSO. In all cell culture media, the final DMSO concentration was adjusted to 1% (v/v). Annexin V was purchased from Invitrogen (Carlsbad, CA). All general solvents and reagents were of HPLC grade or the highest grade commercially available.
| Cell culture
Human PC cell lines (BxPC-3, AsPC-1, Panc-1, and MIA PaCa-2) and the human pancreatic normal epithelial (HPNE) cells were from the American Type Culture Collection (Manassas, VA). FC1245 cells (KPC, murine PC cells) were a gift from Dr. David Tuveson (Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY). We have not authenticated these cell lines, however we routinely test for mycoplasma contamination in every cell line every three months. These cells were grown as monolayers in the specific medium and under conditions suggested by ATCC. All the cell lines were characterized by cell morphology and growth rate and passaged in our laboratory less than 6 months after being received.
| Cell viability assay
Following the treatment with various concentrations of CMC2.24 for 24 h, the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye (MTT), was determined according to the manufacture's protocol (Promega, Madison, WI).
| Clonogenic assay
This was performed as previously described. 21 
| Cytokinetic analysis

| Western blot analysis
Total cell fractions were obtained as previously described. 
| Ras pull-down assays
MIA PaCa-2 cells or primary pancreatic acinar explants were treated with CMC2.24 for 3 h, after which total cell lysates were prepared.
Total amounts of Ras were determined in samples of each lysate by SDS-PAGE followed by immunoblotting with pan-Ras Ab (Thermo Scientific, Rockford, IL). The amounts of Ras-GTP in the lysates were determined by the glutathione-S-transferase (GST)-RBD (Ras-binding domain of Raf) pull-down assay, as previously described. 24 The pulleddown Ras-GTP was subjected to SDS-PAGE followed by immunoblotting with pan-Ras Ab. Protein bands were visualized by enhanced chemiluminescence and quantified by densitometry using the Image J computer software (National Institutes of Health, Bethesda, MD). 
| cRAF overexpression
| Animal studies
All animal studies were approved by the Institutional Animal Care and Use Committee at Stony Brook University.
| Pancreatic epithelial explants culture
Pancreatic epithelial explants from 6 to 8 week-old KrasLSL-G12D/+; Ptf1aCre/+ mice were established following previously published 
| Efficacy study in nude mouse xenografts
We performed three studies as follows:
Panc-1 subcutaneous xenografts: Female immune deficient BALB/c nude mice at 6 weeks of age were purchased from Charles Rivers 
| Immunohistochemical analysis
| Statistical analysis
The data, obtained from at least three independent experiments, were expressed as the mean ± SEM. Statistical evaluation was performed by one-factor analysis of variance (ANOVA) followed by the Tukey test for multiple comparisons. P < 0.05 was regarded as being statistically significant. All the parameters measured, including liver enzymes, were in normal range and there was no significant differences between the groups, suggesting that CMC2.24 350 mg/kg does not affect liver and kidney functions (Supplemental Figure S1 ). Therefore, we determined that the (sub-chronic) maximum tolerated dose of CMC2.24 (3-week period of observation) is at least 350 mg/kg/d.
| CMC2.24 inhibits the growth of pancreatic tumor xenografts
We assessed the in vivo chemotherapeutic potential of CMC2.24 using significantly reduced tumor growth (35% inhibition, P < 0.02; Figure 2B ).
To Figure 2C ), and tumor weight by 55% (P < 0.01; Figure 2D ). Regarding its safety, CMC2.24
was well tolerated, with the mice showing no weight loss or other signs of toxicity during treatment ( Figure 2E ). For instance, on the day of sacrifice, the mean body weight in both groups of mice was as follows: Control group = 24.9 ± 1.5 g; and CMC2.24 group = 23.4 ± 1.2 g.
3.4 | CMC2.24 inhibits the growth of human PC through a strong cytokinetic effect 
| CMC2.24 inhibits ERK signaling pathway in PC cells and xenografts
To elucidate the mechanism of action of CMC2.24, we initially evaluated various key pathways, commonly active in PC, related to cell growth and cell-cycle control, and compared its effect to that of curcumin at same potency (1×IC 50 ). In contrast to curcumin, CMC2.24 had only minor effects on the NF-κB pathway in MIA PaCa-2 cells (Supplemental Figure S2) . However, CMC2.24 strongly affected the ERK pathway, a critical pathway in PC, 29 and this effect by CMC2.24 tended to be stronger than the one exerted by curcumin, even though it did not reach significance between the groups (P = 0.08; Figure 4A ). Figure 4C ). These findings were confirmed by immunofluorescence. CMC significantly reduced p-ERK1/ 2 levels in Panc-1 cells by 48% (P < 0.05; Figure 4D ).
Moreover, CMC2.24 reduced p-ERK1/2 levels in vivo. In total tissue homogenates, isolated form Panc-1 xenografts, CMC2.24 reduced ERK1/2 phosphorylation by 87% (P < 0.02), compared to controls ( Figure 4E ). This effect was also observed in the PDTX model.
Immunostaining of PDTX tissue sections revealed that CMC2.24
reduced the expression of p-ERK1/2 by 89%, compared to control (P < 0.01; Figure 4F ).
We next evaluated whether CMC2.24 could affect the activation of proteins upstream of ERK1/2. For this purpose, we explored the effect of CMC2.24 on the phosphorylation status of MEK, and c-RAF in Panc-1 tumor xenografts. CMC2.24 treatment reduced c-RAF and MEK phosphorylation levels by 93% and 91%, respectively (P < 0.05) compared to controls ( Figure 4E ). The strong effect of CMC2.24 on ERK1/2, MEK, and c-RAF phosphorylation led us to explore the direct effect of CMC2.24 on Ras.
| CMC2.24 inhibits Ras activation
We examined whether or not the PC growth inhibitory effect of CMC2.24 was associated with down regulation of Ras signaling. For this purpose, we used the Ras-GTP pull-down assay. In MIA PaCa-2 cells, CMC2.24 significantly (P < 0.01) inhibited active Ras (Ras-GTP) by 90% ( Figure 5A ).
The inhibition of Ras by CMC2.24 was confirmed in primary acinar explants. We used the Ras-GTP pull-down assay to test the capacity of CMC2.24 to inhibit active Ras in fresh protein lysates from PC acinar cells isolated from active Kras mice. Compared to controls, CMC2.24 at 55 or 80 μM reduced Ras activation in the primary acinar explants by 87% and 90%, respectively (P < 0.01, for both; Figure 5B ).
Taken together, these in vivo results, in agreement with our in vitro results, suggest that Ras is a critical molecular target of CMC2.24, likely accounting for its PC growth inhibitory effect.
3.7 | Overexpression of cRAF reduces, in part, the anticancer effect of CMC2.24
To confirm that the Ras-RAF-MEK-ERK signaling signaling is a key pathway of CMC2.24, we generated MIA PaCa-2 cells overexpressing c-RAF (c-RAF cDNA), using as controls MIA PaCa-2 cells transfected 
| CMC2.24 inhibits STAT3 Ser727 phosphorylation in PC cells
Because ERK1/2 can phosphorylate STAT3 at the Ser727 residue, 30, 31 we explored whether CMC2.24 affected STAT3 activation. In Panc-1 cells, CMC2.24 treatment reduced p-STAT3 Ser727 levels in a timedependent manner, reducing p-STAT3 levels by 60% at 4 h ( Figure 7A ).
This effect was confirmed by immunofluorescence. CMC2.24 1×IC 50 and 1.5×IC 50 significantly reduced p-STAT3 Ser727 levels in Panc-1 cells by 73% and 71%, respectively (P < 0.05; Figure 7B ).
3.9 | CMC2.24 induces mitochondrial reactive oxygen species and intrinsic apoptosis STAT3 can play a role in the mitochondria, as a regulator of the electron transport chain (ETC) and thereby modulating mitochondrial
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production of ATP and reactive oxygen species. 30, 32 Since phosphorylation at the serine 727 residue is critical for the translocation of STAT3 into the mitochondria, 31 Overall, these three preclinical models indicate that CMC2.24 may be efficacious in PC.
CMC2.24 was generated by chemically modifying curcumin in order to enhance its bioavailability and biological activity. 18, 19 Previous studies by our group have shown that CMC2.24 is safe in mice and rats, and CMC2.24 has a better pharmacokinetic profile than curcumin. The innovation behind the development of Mutations in the Kras oncogene constitute one of the key genetic alterations found in PC. Kras activity is not only essential for pancreatic tumor formation and development but, at least in mice, the requirement for Kras is continuous. 5, 6 In addition, oncogenic Kras promotes metabolic reprogramming in pancreatic tumors. 34 Moreover, inactivation of oncogenic Ras in mice results in tumor shrinkage. STAT3 is overexpressed in PC and has been described as a key driver of the progression into advanced PC. [45] [46] [47] Besides its established canonical pathway in which STAT3 functions as a transcription factor, a non-canonical activation pathway of STAT3 has been discovered in which STAT3 holds key functions in the mitochondria. 48, 49 Phosphorylation at the serine 727 residue is critical for the translocation of STAT3 to the mitochondria, and interestingly, ERK may phosphorylate STAT3 at this residue. 31 Given that STAT3 phosphorylation at the serine 727 residue is downstream of ERK, we postulated that CMC2.24 might affect this critical protein in PC.
CMC2.24 reduced STAT3 Ser727 phosphorylation levels, enhanced mitochondrial reactive oxygen species and induced intrinsic apoptosis.
Because of the potential effect of STAT3 in Ras-dependent transformation, 48 and the importance of ERK in its regulation, its down-regulation could explain, in part, the increased in apoptosis observed in CMC2.24-treated PC cells. At this time, the exact mechanisms of the effects of CMC2.24 on mitochondrial STAT3 still remains elusive.
In conclusion, the novel compound CMC2.24 is an effective anticancer agent in preclinical models of PC, acting primarily through the inhibition of Ras activation and its downstream effector ERK1/2.
Taken together, our results point to the potential of CMC2.24, a novel
Ras inhibitor, as a new agent against PC and deserves further evaluation. 
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